Teva Stock Soars on Earnings Beat: Inside Teva’s 2025 Comeback and What’s Next for Investors
Financial Health and Earnings Trends Teva’s financial turnaround appears to be gaining steam, driven by both top-line growth and disciplined cost management. Quarterly revenue has now grown year-over-year for 11 straight quarters investing.com, marking a sustained rebound after a difficult past decade. In Q3 2025, revenue rose ~3% YoY (1% in constant currency) to $4.48 B investing.com, while adjusted earnings jumped to $0.78 per share (from $0.69 a year ago) reuters.com. Notably, this beat Wall Street estimates by ~$0.10 and marked Teva’s strongest earnings surprise of 2025 reuters.com. The growth engines are Teva’s newer branded drugs: movement-disorder treatment Austedo, migraine injection
